VIVXF News and Press, Avivagen From 04/26/21

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances food production and supports immune function, thereby supporting g...

Avivagen (VIVXF) received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta Livestock from UNAHCO.The purchase order is the largest single shipment purchase order of OxC-beta to date and represents a 10% increase in size over its previous record single shipment order."UN...

4.4 tonne order is the largest single shipment purchase in Avivagen’s history Purchase order represents more than 40% of previous fiscal year’s total volume Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporatio...

Ottawa, ON / Business Wire/ April 23, 2021 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely supp...

The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that a total of 3,931 common shares will be issued at the rate of $0.58 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, ...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeti...

Phoenix, Arizona--(Newsfile Corp. - April 6, 2021) - The Stock Day Podcast welcomed Avivagen (OTCQB: VIVXF) ("the Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune f...

Avivagen (VIVXF) announces that it has received approval by the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants.The warrants are exercisable to purchase 2.77M shares at $0.90/share and were originally issued on June 1, 2016. The new date of expiry wi...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, ther...